Suppr超能文献

腺苷受体激动剂和拮抗剂在原发性阵发性肌张力障碍遗传动物模型中的作用。

Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia.

作者信息

Richter A, Hamann M

机构信息

Department of Pharmacology, Toxicology and Pharmacy, School of Veterinary Medicine Hannover, Bünteweg 17, 30559 Hannover, Germany.

出版信息

Br J Pharmacol. 2001 Sep;134(2):343-52. doi: 10.1038/sj.bjp.0704268.

Abstract
  1. Recent studies have shown beneficial effects of an adenosine A(2A) receptor agonist in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress and consumption of coffee can precipitate dystonic attacks. This prompted us to examine the effects of adenosine receptor agonists and antagonists on severity of dystonia in dt(sz) hamsters in more detail. 2. The non-selective adenosine A(1)/A(2A) receptor antagonists, caffeine (10 - 20 mg kg(-1) i.p.) and theophylline (10 - 30 mg kg(-1) s.c.), worsened the dystonia in dt(sz) hamsters. 3. Aggravation of dystonia was also caused by the selective adenosine A(1)/A(2A) antagonist CGS 15943 (9-chloro2-2-furyl)[1,2,4]triazolo[1,5-c]quinazolin-5-amine) at a dose of 30 mg kg(-1) i.p. and by the adenosine A(1) antagonist DPCPX (8-cyclopentyl-1,3-dipropylxanthine; 20 - 30 mg kg(-1) i.p.), while the A(2) antagonist DMPX (3,7-dimethyl-1-propargylxanthine; 2 - 4 mg kg(-1) i.p.) and the highly selective A(2A) antagonist ZM 241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol; 2 - 5 mg kg(-1) i.p.) failed to exert any effects on dystonia. 4. In contrast to the antagonists, both the adenosine A(1) receptor agonist CPA (N(6)-cyclopentyladenosine; 0.1 - 1.0 mg kg(-1) i.p.) and the A(2A) agonist CGS 21680 (2p-(2carboxyethylphen-ethylamino-5'-N-ethylcarboxamindoadenosine; 0.1 - 2.0 mg kg(-1) i.p.) exerted a striking improvement of dystonia. 5. These data suggest that the precipitating effects of methylxanthines are, at least in part, related to their adenosine receptor antagonistic action. 6. Although adenosine receptor agonists can be regarded as interesting candidates for the therapy of paroxysmal dystonia, adverse effects may limit the therapeutic potential of adenosine A(1) agonists, while beneficial effects of the adenosine A(2A) agonist CGS 21680 were already found at well tolerated doses.
摘要
  1. 最近的研究表明,腺苷A(2A)受体激动剂对dt(sz)突变仓鼠有益,dt(sz)突变仓鼠是阵发性肌张力障碍的动物模型,其中应激和饮用咖啡会诱发肌张力障碍发作。这促使我们更详细地研究腺苷受体激动剂和拮抗剂对dt(sz)仓鼠肌张力障碍严重程度的影响。2. 非选择性腺苷A(1)/A(2A)受体拮抗剂咖啡因(10 - 20毫克/千克腹腔注射)和茶碱(10 - 30毫克/千克皮下注射)会使dt(sz)仓鼠的肌张力障碍恶化。3. 选择性腺苷A(1)/A(2A)拮抗剂CGS 15943(9-氯-2-呋喃基)[1,2,4]三唑并[1,5-c]喹唑啉-5-胺)以30毫克/千克腹腔注射的剂量以及腺苷A(1)拮抗剂DPCPX(8-环戊基-1,3-二丙基黄嘌呤;20 - 30毫克/千克腹腔注射)也会导致肌张力障碍加重,而A(2)拮抗剂DMPX(3,7-二甲基-1-丙炔基黄嘌呤;2 - 4毫克/千克腹腔注射)和高选择性A(2A)拮抗剂ZM 241385(4-(2-[7-氨基-2-(2-呋喃基)[1,2,4]三唑并[2,3-a][1,3,5]三嗪-5-基氨基]乙基)苯酚;2 - 5毫克/千克腹腔注射)对肌张力障碍没有任何影响。4. 与拮抗剂相反,腺苷A(1)受体激动剂CPA(N(6)-环戊基腺苷;0.1 - 1.0毫克/千克腹腔注射)和A(2A)激动剂CGS 21680(2p-(2-羧乙基苯乙氨基-5'-N-乙基羧酰胺腺苷;0.1 - 2.0毫克/千克腹腔注射)都能显著改善肌张力障碍。5. 这些数据表明,甲基黄嘌呤的诱发作用至少部分与其腺苷受体拮抗作用有关。6. 尽管腺苷受体激动剂可被视为阵发性肌张力障碍治疗的有趣候选药物,但不良反应可能会限制腺苷A(1)激动剂的治疗潜力,而腺苷A(2A)激动剂CGS 21680在耐受性良好的剂量下已显示出有益效果。

相似文献

2
Decreased adenosine receptor binding in dystonic brains of the dt(sz) mutant.
Neuroscience. 2005;134(1):33-8. doi: 10.1016/j.neuroscience.2005.03.033.
7
Adenosine analogues relax guinea-pig taenia caeci via an adenosine A2B receptor and a xanthine-resistant site.
Eur J Pharmacol. 1997 Mar 26;323(1):103-6. doi: 10.1016/s0014-2999(97)00113-1.
9
CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia.
Eur J Pharmacol. 2000 Sep 22;404(3):299-302. doi: 10.1016/s0014-2999(00)00627-0.

本文引用的文献

1
CGS 21680 exerts marked antidystonic effects in a genetic model of paroxysmal dyskinesia.
Eur J Pharmacol. 2000 Sep 22;404(3):299-302. doi: 10.1016/s0014-2999(00)00627-0.
3
Fine-tuning neuromodulation by adenosine.通过腺苷微调神经调节
Trends Pharmacol Sci. 2000 Sep;21(9):341-6. doi: 10.1016/s0165-6147(00)01517-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验